Oncology Drug Advisory Committee
From Wikipedia, the free encyclopedia
The Oncology Drugs Advisory Committee (ODAC) receives requests for technical and clinical evaluation of new drugs by the US FDA. The committee, consisting of members from academic and clinical oncology biostatistics, the general public, and the pharmaceutical industry, makes non-binding recommendations to both the CDER and CBER divisions of the FDA about the advisability of approving new medications to treat cancer.
ODAC meetings are held regularly; the most recent meeting was held in March 12th and 13th 2008 in Gaithersburg, MD.
The current roster of ODAC members is publicly available. [1]
 |
This oncology article is a stub. You can help Wikipedia by expanding it. |
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
